BINSA Act
Sponsored By: Representative Moolenaar, John R. [R-MI-2]
Introduced
Summary
This bill would expand the Defense Production Act to treat certain biotechnology transfers as national-security sensitive, with a focus on pharmaceutical and biologics licensing, know-how, and manufacturing. It would push agencies to write rules and report on U.S. capital flowing to biotech sectors tied to the People’s Republic of China.
Show full summary
- U.S. biotechnology companies and researchers would face tighter screening for licensing, joint ventures, and equity investments that involve drug discovery platforms, clinical development capabilities, or biologics manufacturing. These activities could be placed in prohibited or notifiable technology categories.
- Investors and dealmakers would see higher scrutiny for cross-border transactions that transfer pharmaceutical innovation capacity or manufacturing know-how to entities subject to PRC direction or control. Treasury rulemaking would single out IP licensing and platform transfers as priority areas.
- Federal agencies and Congress would get new steps to act on this risk. Treasury must issue a defining rule within 1 year with HHS, Defense, and intelligence consultation. Defense must deliver an unclassified report, with a possible classified annex, to specified congressional committees within 60 days.
Personalized for You
How does this bill affect your finances?
Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 0 benefits, 0 costs, 1 mixed.
New biotech screening for investors
This bill would expand the Defense Production Act to cover research, development, manufacturing, and commercialization of drugs, biologics, and therapeutic compounds. It would add licensing a prohibited technology from a covered foreign person to the list of activities the Act can screen and control. The Treasury Secretary would have to issue a rule within one year, after consulting HHS, the Department of Defense, and the Director of National Intelligence. That rule would prioritize licensing, joint ventures, and equity investments involving drug discovery platforms, clinical R&D, and biologics manufacturing, and would exclude agricultural biotech, unrelated industrial fermentation, and basic academic research. If enacted, firms and investors would face more DPA reviews and limits, but they would get clearer rules about what is covered.
Sponsors & CoSponsors
Sponsor
Moolenaar, John R. [R-MI-2]
MI • R
Cosponsors
Rep. Dingell, Debbie [D-MI-6]
MI • D
Sponsored 6/2/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov